Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications

Michele Caraglia, A. Budillon, P. Tagliaferri, M. Marra, A. Abbruzzese, F. Caponigro

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Cell proliferation, differentiation, and survival are regulated by a number of extracellular hormones, growth factors, and cytokines in complex organisms. The transduction of the signals by these factors from the outside to the nucleus often requires the presence of small intracellular proteins (i.e. ras and other small G proteins) that are linked to the plasma membrane through a isoprenyl residue that functions as hydrophobic anchor. Isoprenylation is a complex process regulated by different enzymatic steps that could represent potential molecular targets for anti-cancer strategies. In the present paper the different transduction pathways regulated by some isoprenylated proteins such as ras and other small G proteins are described. Moreover, the molecular mechanisms of the isoprenylation process and the mode of action of the different isoprenylation inhibitors are discussed with attention to statins, farnesyltransferase inhibitors (FTI) and aminobisphosphonates. The role of different candidate targets in the determination of anti-tumour effects by FTIs is also described in order to define potential molecular markers predictor of clinical response. On the basis of several preclinical data, new strategies based on multi-step enzyme inhibition or on target prioritization are proposed in order to enhance the anti-tumour activity of agents inhibiting isoprenylation. Finally, a summary of the principal data on clinical trials based on the use of FTIs and statins is given. In conclusion, the inhibition of isoprenylation is an attractive, but still not completely investigated therapeutic alternative that requires optimization for the translation in the current treatment of neoplasms.

Original languageEnglish
Pages (from-to)301-323
Number of pages23
JournalCurrent Drug Targets
Volume6
Issue number3
DOIs
Publication statusPublished - May 2005

Fingerprint

Protein Prenylation
Prenylation
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Monomeric GTP-Binding Proteins
Tumors
Farnesyltranstransferase
Enzyme inhibition
Hormones
Cell proliferation
Cell membranes
Anchors
Neoplasms
Intercellular Signaling Peptides and Proteins
Proteins
Cytokines
Therapeutics
ras Proteins
Cell Differentiation
Signal Transduction
Cell Survival

Keywords

  • Aminobisphosphonates
  • Farnesyltransferase inhibitors
  • Farnesyltransferases
  • Geranylgeranyltransferases
  • Isoprenylation
  • Ras
  • Small G proteins
  • Statins

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms : Preclinical and clinical implications. / Caraglia, Michele; Budillon, A.; Tagliaferri, P.; Marra, M.; Abbruzzese, A.; Caponigro, F.

In: Current Drug Targets, Vol. 6, No. 3, 05.2005, p. 301-323.

Research output: Contribution to journalArticle

@article{a6fa7c0e1a234e3fa74cf57b721a66d1,
title = "Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications",
abstract = "Cell proliferation, differentiation, and survival are regulated by a number of extracellular hormones, growth factors, and cytokines in complex organisms. The transduction of the signals by these factors from the outside to the nucleus often requires the presence of small intracellular proteins (i.e. ras and other small G proteins) that are linked to the plasma membrane through a isoprenyl residue that functions as hydrophobic anchor. Isoprenylation is a complex process regulated by different enzymatic steps that could represent potential molecular targets for anti-cancer strategies. In the present paper the different transduction pathways regulated by some isoprenylated proteins such as ras and other small G proteins are described. Moreover, the molecular mechanisms of the isoprenylation process and the mode of action of the different isoprenylation inhibitors are discussed with attention to statins, farnesyltransferase inhibitors (FTI) and aminobisphosphonates. The role of different candidate targets in the determination of anti-tumour effects by FTIs is also described in order to define potential molecular markers predictor of clinical response. On the basis of several preclinical data, new strategies based on multi-step enzyme inhibition or on target prioritization are proposed in order to enhance the anti-tumour activity of agents inhibiting isoprenylation. Finally, a summary of the principal data on clinical trials based on the use of FTIs and statins is given. In conclusion, the inhibition of isoprenylation is an attractive, but still not completely investigated therapeutic alternative that requires optimization for the translation in the current treatment of neoplasms.",
keywords = "Aminobisphosphonates, Farnesyltransferase inhibitors, Farnesyltransferases, Geranylgeranyltransferases, Isoprenylation, Ras, Small G proteins, Statins",
author = "Michele Caraglia and A. Budillon and P. Tagliaferri and M. Marra and A. Abbruzzese and F. Caponigro",
year = "2005",
month = "5",
doi = "10.2174/1389450053765833",
language = "English",
volume = "6",
pages = "301--323",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms

T2 - Preclinical and clinical implications

AU - Caraglia, Michele

AU - Budillon, A.

AU - Tagliaferri, P.

AU - Marra, M.

AU - Abbruzzese, A.

AU - Caponigro, F.

PY - 2005/5

Y1 - 2005/5

N2 - Cell proliferation, differentiation, and survival are regulated by a number of extracellular hormones, growth factors, and cytokines in complex organisms. The transduction of the signals by these factors from the outside to the nucleus often requires the presence of small intracellular proteins (i.e. ras and other small G proteins) that are linked to the plasma membrane through a isoprenyl residue that functions as hydrophobic anchor. Isoprenylation is a complex process regulated by different enzymatic steps that could represent potential molecular targets for anti-cancer strategies. In the present paper the different transduction pathways regulated by some isoprenylated proteins such as ras and other small G proteins are described. Moreover, the molecular mechanisms of the isoprenylation process and the mode of action of the different isoprenylation inhibitors are discussed with attention to statins, farnesyltransferase inhibitors (FTI) and aminobisphosphonates. The role of different candidate targets in the determination of anti-tumour effects by FTIs is also described in order to define potential molecular markers predictor of clinical response. On the basis of several preclinical data, new strategies based on multi-step enzyme inhibition or on target prioritization are proposed in order to enhance the anti-tumour activity of agents inhibiting isoprenylation. Finally, a summary of the principal data on clinical trials based on the use of FTIs and statins is given. In conclusion, the inhibition of isoprenylation is an attractive, but still not completely investigated therapeutic alternative that requires optimization for the translation in the current treatment of neoplasms.

AB - Cell proliferation, differentiation, and survival are regulated by a number of extracellular hormones, growth factors, and cytokines in complex organisms. The transduction of the signals by these factors from the outside to the nucleus often requires the presence of small intracellular proteins (i.e. ras and other small G proteins) that are linked to the plasma membrane through a isoprenyl residue that functions as hydrophobic anchor. Isoprenylation is a complex process regulated by different enzymatic steps that could represent potential molecular targets for anti-cancer strategies. In the present paper the different transduction pathways regulated by some isoprenylated proteins such as ras and other small G proteins are described. Moreover, the molecular mechanisms of the isoprenylation process and the mode of action of the different isoprenylation inhibitors are discussed with attention to statins, farnesyltransferase inhibitors (FTI) and aminobisphosphonates. The role of different candidate targets in the determination of anti-tumour effects by FTIs is also described in order to define potential molecular markers predictor of clinical response. On the basis of several preclinical data, new strategies based on multi-step enzyme inhibition or on target prioritization are proposed in order to enhance the anti-tumour activity of agents inhibiting isoprenylation. Finally, a summary of the principal data on clinical trials based on the use of FTIs and statins is given. In conclusion, the inhibition of isoprenylation is an attractive, but still not completely investigated therapeutic alternative that requires optimization for the translation in the current treatment of neoplasms.

KW - Aminobisphosphonates

KW - Farnesyltransferase inhibitors

KW - Farnesyltransferases

KW - Geranylgeranyltransferases

KW - Isoprenylation

KW - Ras

KW - Small G proteins

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=18744363084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744363084&partnerID=8YFLogxK

U2 - 10.2174/1389450053765833

DO - 10.2174/1389450053765833

M3 - Article

C2 - 15857290

AN - SCOPUS:18744363084

VL - 6

SP - 301

EP - 323

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 3

ER -